Literature DB >> 14968374

Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.

Seok-Gu Kang1, Chung Hun Ryu, Sin Soo Jeun, Chun Kun Park, Hyung-Jin Shin, Jong Hyun Kim, Moon Chan Kim, Joon Ki Kang.   

Abstract

OBJECTS: The aims of this study were to assess the cytotoxic capability of lymphokine-activated killer (LAK) cells from umbilical cord blood (UCB), to compare them with those of peripheral blood (PB)-derived cells against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671), and to identify which mechanism and genes were involved in cytotoxicity.
METHODS: The effector cells were generated by interleukin-2 from UCB and PB. The antitumor property of effector cells against the target cells (U87, TE671) were estimated using a visual survival cell assay. The mixed target and effector (UCB) cells were analyzed for whether DNA fragmentation was present or not. Reverse transcription polymerase chain reaction analysis was then performed to estimate the statement of the perforin and FasL genes in activated and inactivated cells from UCB.
RESULTS: The higher in vitro antitumor properties of the LAK cells from UCB were observed in comparison to the LAK cells from PB against the U87 and the TE671 ( p<0.05). Apoptosis may be one of the lysis mechanisms of target cells by the LAK cells from UCB. The contributing genes could be FasL and perforin.
CONCLUSIONS: This study suggests that UCB may be used as a source of LAK cells in adults and children suffering from anaplastic astrocytoma or medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968374     DOI: 10.1007/s00381-003-0898-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  56 in total

1.  Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.

Authors:  F Fagioli; E Biasin; M Berger; F Nesi; E H Saroglia; R Miniero; S Martino; P A Tovo
Journal:  Bone Marrow Transplant       Date:  2003-01       Impact factor: 5.483

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Ontogeny of phytohemagglutinin-induced gamma interferon by leukocytes of healthy infants and children: evidence for decreased production in infants younger than 2 months of age.

Authors:  L Frenkel; Y J Bryson
Journal:  J Pediatr       Date:  1987-07       Impact factor: 4.406

4.  Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.

Authors:  Y Fujimiya; Y Suzuki; R Katakura; T Ohno
Journal:  J Hematother       Date:  1999-02

5.  X-gene product of hepatitis B virus induces apoptosis in liver cells.

Authors:  H Kim; H Lee; Y Yun
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

6.  Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.

Authors:  J Yoshida; T Takaoka; M Mizuno; H Momota; H Okada
Journal:  J Surg Oncol       Date:  1996-07       Impact factor: 3.454

7.  Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I.

Authors:  M J Smyth; M J McGuire; K Y Thia
Journal:  J Immunol       Date:  1995-06-15       Impact factor: 5.422

8.  Fetal natural killer cell function is suppressed.

Authors:  E Dominguez; J A Madrigal; Z Layrisse; S B Cohen
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

9.  Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease.

Authors:  D T Harris; J LoCascio; F J Besencon
Journal:  Bone Marrow Transplant       Date:  1994-10       Impact factor: 5.483

10.  Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.

Authors:  C A Kruse; D H Mitchell; K O Lillehei; S D Johnson; E L McCleary; G E Moore; S Waldrop; G W Mierau
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

View more
  6 in total

1.  Cytotoxicity of rat marrow stromal cells against malignant glioma cells.

Authors:  Seok-Gu Kang; Sin Soo Jeun; Jung Yeon Lim; Do Sung Yoo; Pil Woo Huh; Kyung Souk Cho; Dal Soo Kim; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2005-06-03       Impact factor: 1.475

2.  Induction of apoptosis in glioma cells requires cell-to-cell contact with human umbilical cord blood stem cells.

Authors:  Christopher S Gondi; Venkateswara R Gogineni; Chandramu Chetty; Venkata R Dasari; Bharathi Gorantla; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

Review 3.  Medulloblasoma: challenges for effective immunotherapy.

Authors:  Adam M Sonabend; Alfred T Ogden; Lisa M Maier; David E Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson
Journal:  J Neurooncol       Date:  2011-12-16       Impact factor: 4.130

4.  Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells.

Authors:  Seok-Gu Kang; Sin Soo Jeun; Jung Yeon Lim; Seong Muk Kim; Yoon Sun Yang; Won Il Oh; Pil-Woo Huh; Chun Kun Park
Journal:  Childs Nerv Syst       Date:  2007-10-30       Impact factor: 1.475

Review 5.  Immunotherapy for Medulloblastoma: Current Perspectives.

Authors:  Tanvir F Kabir; Charles A Kunos; John L Villano; Aman Chauhan
Journal:  Immunotargets Ther       Date:  2020-04-20

6.  Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.

Authors:  Allison B Powell; Sridevi Yadavilli; Devin Saunders; Stacey Van Pelt; Elizabeth Chorvinsky; Rachel A Burga; Shuroug Albihani; Patrick J Hanley; Zhenhua Xu; Yanxin Pei; Eric S Yvon; Eugene I Hwang; Catherine M Bollard; Javad Nazarian; Conrad Russell Y Cruz
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.